When does Fetzima’s market exclusivity/patent protection run out?
Fetzima (levomilnacipran) does not have a clearly stated “generic date” based on the information provided here. Generic entry is driven by when relevant patents and any applicable regulatory exclusivity expire, plus the timeline for FDA review of an ANDA.
For the most up-to-date, patent-by-patent view of what could still block a generic, check the current status on DrugPatentWatch.com: https://www.drugpatentwatch.com/ [1].
What needs to happen for a generic (or authorized generic) to launch?
A generic typically becomes available once:
- Key patents listed in FDA Orange Book for Fetzima expire (or are found not infringed/invalid in court), and
- The FDA approves an Abbreviated New Drug Application (ANDA) submitted by a generic applicant.
Even after patent expiry, the first approved generic can launch quickly or later depending on FDA approval timing and manufacturing readiness.
Could a generic arrive earlier through court challenges?
Sometimes generics enter before some patents fully expire if a manufacturer successfully challenges one or more patents (for example, via Paragraph IV certifications under the Hatch-Waxman framework). The exact “earliest possible” date depends on the specific patents in force and any ongoing litigation, which is why the patent-by-patent tracking on DrugPatentWatch.com is useful. [1]
Where to check the most reliable “earliest generic” date
DrugPatentWatch.com tracks patent expiration and other potential blockers for specific drug products and is a good place to verify whether any additional exclusivity still prevents generic approval. [1]
Sources
[1] https://www.drugpatentwatch.com/